Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury

被引:261
作者
Lang, Carmen
Meier, Yvonne
Stieger, Bruno
Beuers, Ulrich
Lang, Thomas
Kerb, Reinhold
Kullak-Ublick, Gerd A.
Meier, Peter J.
Pauli-Magnus, Christiane
机构
[1] Univ Zurich Hosp, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, CH-8091 Zurich, Switzerland
[3] Univ Munich, Klinikum Grosshadern, Dept Med 2, D-8000 Munich, Germany
[4] Epidauros Biotechnol Co, Bernried, Germany
关键词
BSEP; drug-induced liver injury; hepatocellular transporters; MDR3; pharmacogenetics;
D O I
10.1097/01.fpc.0000230418.28091.76
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives Increasing evidence suggests that a genetically determined functional impairment of the hepatocellular efflux transporters bile salt export pump (BSEP, ABCB11) and multidrug resistance protein 3 (MDR3, ABCB4) play a pathophysiological role in the development of drug-induced liver injury. The aim of this study was therefore to describe the extent of genetic variability in ABCB11 and ABCB4 in patients with drug-induced liver injury and to in vitro functionally characterize newly detected ABCB11 mutations and polymorphisms. Methods ABCB11 and ABCB4 were sequenced in 23 patients with drug-induced cholestasis and 13 patients with drug-induced hepatocellular injury. Ninety-five healthy Caucasians served as the control group. Reference and mutant BSEP were expressed in Sf9 cells and ATP-dependent transport of [3 HI-taurocholate was measured in a rapid filtration assay. Results Four highly conserved nonsynonymous mutations were specific for drug-induced liver injury [ABCB11: D676Y (drug-induced cholestasis) and G855R (drug-induced cholestasis); ABCB4: 1764L (drug-induced cholestasis) and L10820 (drug-induced hepatocellular injury)]. Furthermore, a polymorphism in exon 13 of ABCB11 (V444A), which is associated with decreased hepatic BSEP expression was significantly more frequent in drug-induced cholestasis patients than in drug-induced hepatocellular injury patients and healthy controls (76 versus 50 and 59% in drug-induced cholestasis patients, drug-induced hepatocellular injury patients and healthy controls, respectively; P < 0.05). The in-vitro transport activity of the V444A and the D676Y BSEP constructs was similar, whereas the G855R mutation was nonfunctional. Conclusion In summary, our data support a role of ABCB11 and ABCB4 mutations and polymorphisms in drug-induced cholestasis. Genotyping of selected patients with acquired cholestasis might help to identify individuals with a genetic predisposition.
引用
收藏
页码:47 / 60
页数:14
相关论文
共 30 条
[1]  
BANKOWSKI Z, 1990, INT J CLIN PHARM TH, V28, P317
[2]   Drug-induced liver injury: Mechanisms and test systems [J].
Bissell, DM ;
Gores, GJ ;
Laskin, DL ;
Hoofnagle, JH .
HEPATOLOGY, 2001, 33 (04) :1009-+
[3]   Mammalian ABC transporters in health and disease [J].
Borst, P ;
Elferink, RO .
ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 :537-592
[4]   The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors [J].
Byrne, JA ;
Strautnieks, SS ;
Mieli-Vergani, G ;
Higgins, CF ;
Linton, KJ ;
Thompson, RJ .
GASTROENTEROLOGY, 2002, 123 (05) :1649-1658
[5]   Hepatotoxicity of commonly used drugs: Nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs [J].
Chitturi, S ;
George, J .
SEMINARS IN LIVER DISEASE, 2002, 22 (02) :169-183
[6]   Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis [J].
De Vree, JML ;
Jacquemin, E ;
Sturm, E ;
Cresteil, D ;
Bosma, PJ ;
Aten, J ;
Deleuze, JF ;
Desrochers, M ;
Burdelski, M ;
Bernard, O ;
Elferink, RPJO ;
Hadchouel, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :282-287
[7]   The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions [J].
Fattinger, K ;
Funk, C ;
Pantze, M ;
Weber, C ;
Reichen, J ;
Stieger, B ;
Meier, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (04) :223-231
[8]   Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat [J].
Funk, C ;
Ponelle, C ;
Scheuermann, G ;
Pantze, M .
MOLECULAR PHARMACOLOGY, 2001, 59 (03) :627-635
[9]   Progressive familial intrahepatic cholestasis type 3 revealed by oral contraceptive pills [J].
Ganne-Carrié, N ;
Baussan, C ;
Grando, V ;
Gaudelus, J ;
Cresteil, D ;
Jacquemin, E .
JOURNAL OF HEPATOLOGY, 2003, 38 (05) :693-694
[10]   The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver [J].
Gerloff, T ;
Stieger, B ;
Hagenbuch, B ;
Madon, J ;
Landmann, L ;
Roth, J ;
Hofmann, AF ;
Meier, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :10046-10050